Browse Title Index

Issue Title
Vol 19, No 3 (2012) Corrigendum: A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada Details   PDF   HTML
V. Hirsh, B. Melosky, G. Goss, D. Morris, W. Morzycki
Vol 23, No 5 (2016) Corrigendum: Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study Abstract   PDF   HTML
S.F. Hall, R. Griffiths
Vol 23, No 4 (2016) Corrigendum: Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014 Abstract   PDF   HTML
E. Tsvetkova, S. Sud, N. Aucoin, J. Biagi, R. Burkes, B. Samson, S. Brule, C. Cripps, B. Colwell, C. Falkson, M. Dorreen, R. Goel, F. Halwani, C. Marginean, C. Marginean, J. Maroun, N. Michaud, M. Tehfe, M. Thirlwell, M. Vickers, T. Asmis
Vol 18, No 6 (2011) Corrigendum: Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective Abstract   PDF   HTML
A. Oza
Vol 19, No 1 (2012) Corrigendum: Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba Abstract   PDF   HTML
Current Oncology
Vol 20, No 3 (2013) Corrigendum: Ubiquitin pathway and ovarian cancer Abstract   PDF   HTML
Z. Rao, Y. Ding
Vol 24, No 5 (2017) Cost analysis of breast cancer diagnostic assessment programs Abstract   PDF   HTML
G.N. Honein-AbouHaidar, J.S. Hoch, M.J. Dobrow, T. Stuart-McEwan, D.R. McCready, A.R. Gagliardi
Vol 23 (2016): Original Cancer Costing Research Using Canadian Data Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis Abstract   PDF   HTML
I. Cromwell, Z. Ferreira, L. Smith, K. van der Hoek, G. Ogilvie, A. Coldman, S.J. Peacock
Vol 17, No 1 (2010) Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer Abstract   PDF
N. Mittmann, S. Verma, M. Koo, K. Alloul, M. Trudeau
Vol 23, No 3 (2016) Cost impact analysis of Enhanced Recovery After Surgery program implementation in Alberta colon cancer patients Abstract   PDF   HTML
G. Nelson, L.N. Kiyang, A. Chuck, N.X. Thanh, L.M. Gramlich
Vol 23 (2016): Original Cancer Costing Research Using Canadian Data Cost implications of unwarranted imaging for distant metastasis in women with early-stage breast cancer in Ontario Abstract   PDF   HTML
K. Thavorn, Z. Wang, D. Fergusson, S. van Katwyk, A. Arnaout, M. Clemons
Vol 23 (2016): Original Cancer Costing Research Using Canadian Data Cost trajectories for cancer patients Abstract   PDF   HTML
W.P Wodchis, E. Arthurs, A.I. Khan, S. Gandhi, M. MacKinnon, J. Sussman
Vol 26, No 5 (2019) Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer Abstract   PDF   HTML
W. W.L. Wong, M. Zargar, S. R. Berry, Y. J. Ko, M. Riesco-Martínez, K. K.W. Chan
Vol 23 (2016): Original Cancer Costing Research Using Canadian Data Cost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservation Abstract   PDF   HTML
N.J. Look Hong, G.M. Clarke, M.J. Yaffe, C.M.B. Holloway
Vol 21, No 1 (2014) Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes Abstract   PDF   HTML
A.R. Levy, D. Zou, N. Risebrough, R. Buckstein, T. Kim, N. Brereton
Vol 25, No 1 (2018) Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada Abstract   PDF   HTML
A. Chua, A. Perrin, J.F. Ricci, M.P. Neary, M. Thabane
Vol 21, No 4 (2014) Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer Abstract   PDF   HTML
E.M. Ewara, G.S. Zaric, S. Welch, S. Sarma
Vol 21, No 1 (2014) Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer Abstract   PDF   HTML
C.L. Attard, S. Brown, K. Alloul, M.J. Moore
Vol 20, No 5 (2013) Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada Abstract   PDF   HTML
T.E. Delea, J. Amdahl, A. Chit, M.M. Amonkar
Vol 17, No 1 (2010) Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada Abstract   PDF
C.L. Attard, J.A. Maroun, K. Alloul, D.T. Grima, L.M. Bernard
Vol 23, No 4 (2016) Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada Abstract   PDF   HTML
J. Amdahl, J. Diaz, J. Park, H.R. Nakhaipour, T.E. Delea
Vol 21, No 6 (2014) Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada Abstract   PDF   HTML
T.E. Delea, J. Amdahl, H.R. Nakhaipour, S.C. Manson, A. Wang, N. Fedor, A. Chit
Vol 23, No 4 (2016) Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals Abstract   PDF   HTML
J. Beca, K.K.W. Chan
Vol 20, No 2 (2013) Cost-effectiveness of systemic therapies for metastatic pancreatic cancer Abstract   PDF   HTML
V.C. Tam, Y.J. Ko, N. Mittmann, M.C. Cheung, K. Kumar, S. Hassan, K.K.W. Chan
Vol 19, No 6 (2012) Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma Abstract   PDF   HTML
T. E. Delea, K. El Ouagari, J. Rotter, A. Wang, S. Kaura, G.J. Morgan
Vol 26, No 2 (2019) Cost-of-illness study for non-small-cell lung cancer using real-world data Abstract   PDF   HTML
S.J. Seung, M. Hurry, S. Hassan, R. N. Walton, W. K. Evans
Vol 23, No 2 (2016) Costs of cervical cancer treatment: population-based estimates from Ontario Abstract   PDF   HTML
C. Pendrith, A. Thind, G.S. Zaric, S. Sarma
Vol 26, No 5 (2019) Cost–utility analysis of 21-gene assay for node-positive early breast cancer Abstract   PDF   Supplemental Material   HTML
L. Masucci, S. Torres, A. Eisen, M. Trudeau, I. Tyono, H. Saunders, K. W. Chan, W. Isaranuwatchai
Vol 22, No 4 (2015) Cost–utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels Abstract   PDF   HTML
N.W.D. Lamond, C. Skedgel, D. Rayson, T. Younis
Vol 19, No 4 (2012) Countercurrents / Is breast cancer staging obsolete? Abstract   PDF   HTML
S. A. Narod
Vol 19, No 3 (2012) Countercurrents / The tip of the iceberg Details   PDF   HTML
S.A. Narod
Vol 20, No 2 (2013) Countercurrents: A new kind of breast cancer gene mutation Details   PDF   HTML
S.A. Narod
Vol 23, No 5 (2016) Countercurrents: Do acronyms belong in the medical literature? Abstract   PDF   HTML
S.A. Narod, H. Ahmed, M.R. Akbari
Vol 26, No 3 (2019) Countercurrents: Is now the right time to pull the plug on mammography? Abstract   PDF   HTML
S. A. Narod
Vol 20, No 3 (2013) Countercurrents: Salpingectomy to prevent ovarian cancer Abstract   PDF   HTML
S.A. Narod
Vol 26, No 6 (2019) Countercurrents: The bias of choice Abstract   PDF   HTML
S. A. Narod
Vol 22, No 3 (2015) Counterpoint re: “Mammography screening—sticking to the science” Abstract   PDF   HTML
S.A. Narod
Vol 26, No 4 (2019) Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective Abstract   PDF   HTML
D. G. Bebb, J. Agulnik, R. Albadine, S. Banerji, G. Bigras, C. Butts, C. Couture, J. C. Cutz, P. Desmeules, D. N. Ionescu, N. B. Leighl, B. Melosky, W. Morzycki, F. Rashid-Kolvear, H. S. Sekhon, A. C. Smith, T. L. Stockley, E. Torlakovic, Z. Xu, M. S. Tsao
Vol 26, No 3 (2019) Crocodiles and alligators: physicians’ answer to cancer? Abstract   PDF   HTML
N. A. Khan, M. Soopramanien, R. Siddiqui
Vol 13, No 4 (2006) Cross-Border Referral for Early Breast Cancer: An Analysis of Radiation Fractionation Patterns Abstract   PDF
Ian S Dayes, Timothy J Whelan, Jim A Julian, Michael R Kuettel, Dybesh Regmi, Gordon S Okawara, Malti Patel, Harold I Reiter, Sacha Dubois
Vol 26, No 5 (2019) Cross-Canada differences in early-stage breast cancer treatment and acute-care use Abstract   PDF   HTML
M. Powis, P. Groome, N. Biswanger, C. Kendell, K. M. Decker, E. Grunfeld, M. L. McBride, R. Urquhart, M. Winget, G. A. Porter, M. K. Krzyzanowska
Vol 23, No 5 (2016) Cross-comparison of cancer drug approvals at three international regulatory agencies Abstract   PDF   HTML
N. Samuel, S. Verma
Vol 20, No 6 (2013) Cross-disciplinary research in cancer: an opportunity to narrow the knowledge– practice gap Abstract   PDF   HTML
R. Urquhart, E. Grunfeld, L. Jackson, J. Sargeant, G.A. Porter
Vol 26 (2019): Advances in Colorectal Cancer: Translating Best Evidence to Practice Current and emerging biomarkers in metastatic colorectal cancer Abstract   PDF   HTML   Erratum
M.K.C. Lee, J. M. Loree
Vol 22, No 5 (2015) Current definition of locally advanced breast cancer Abstract   PDF   HTML
P.K. Garg, G. Prakash
Vol 25, No 5 (2018) Current landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges. Abstract   PDF   HTML
N. A. Nixon, N. Blais, S. Ernst, C. Kollmannsberger, G. Bebb, M. Butler, M. Smylie, S. Verma
Vol 25 (2018): Advances in Breast and Lung Cancers for the Community Oncologist Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer Abstract   PDF   HTML
A. Pabani, C.A. Butts
Vol 17 (2010): Managing Prostate Cancer in 2010 and Beyond: A Canadian Perspective Current management of castrate-resistant prostate cancer Abstract   PDF
S. J. Hotte, F. Saad
Vol 18, No 5 (2011) Current Oncology receives its first journal impact factor Details   PDF   HTML
Multimed Inc.
Vol 20, No 1 (2013) Current Oncology: it all started 20 years ago ... Details   PDF   HTML
L. Cooper
Vol 24, No 3 (2017) Current practice in total-body irradiation: results of a Canada-wide survey Abstract   PDF   HTML
R.C.N. Studinski, D.J. Fraser, R.S. Samant, M.S. MacPherson
Vol 22, No 4 (2015) Dasatinib for a child with Philadelphia chromosome–positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy Abstract   PDF   HTML
K.H. Wu, H.P. Wu, T. Weng, C.T. Peng, Y.H Chao
Vol 15 (2008): Supplement - Integrative Oncology: A Canadian and International Perspective Declining conventional cancer treatment and using Complementary and Alternative Medicine: A problem or a challenge? Abstract   PDF
Marja J. Verhoef
Vol 17, No 4 (2010) Dedifferentiated giant cell tumour of bone in the form of low-grade fibroblastic osteogenic sarcoma: case report of a unique presentation with follow-up Abstract   PDF
A. Nahal, A. Ajlan, T. Alcindor, R. Turcotte
Vol 23, No 1 (2016) De-escalation of bone-targeted agents for metastatic prostate cancer Abstract   PDF   HTML
B.Y. Hong, M.F.K. Ibrahim, R. Fernandes, S. Mazzarello, B. Hutton, R. Shorr, M. Clemons
Vol 18, No 3 (2011) Defining the elements for successful implementation of a small-city radiotherapy department Abstract   PDF   HTML
P. Dunscombe, P. S. Craighead
Vol 15, No 4 (2008) Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group Abstract   PDF
Wendy R. Parulekar, Michael McKenzie, Kim N Chi, Laurence Klotz, Charles Catton, Michael Brundage, Keyue Ding, Andrea Hiltz, Ralph Meyer, Fred Saad
Vol 16, No 1 (2009) Demographic Profile and Utilization Statistics of a Canadian Inpatient Palliative Care Unit Within a Tertiary Care Setting Abstract   PDF
Julie Napolskikh, Debbie Selby, Margaret Bennett, Edward Chow, Kristin Harris, Emily Sinclair, Jeff Myers
Vol 20, No 5 (2013) Denosumab and giant cell tumour of bone—a review and future management considerations Abstract   PDF   HTML
S.F. Xu, B. Adams, X.C. Yu, M. Xu
Vol 26, No 5 (2019) Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre Abstract   PDF   HTML
K. Uminski, K. Brown, O. Bucher, I. Hibbert, D. H. Dhaliwal, J. B. Johnston, M. Geirnaert, D. E. Dawe, V. Banerji
Vol 21, No 5 (2014) Design and implementation of a community-based exercise program for breast cancer patients Abstract   PDF   HTML
H.J. Leach, J.M. Danyluk, S.N. Culos-Reed
Vol 15, No 5 (2008) Developing a Methodology for 3-D Correlation of PET-CT Images and Whole-Mount Histopathology in Non-Small Cell Lung Cancer Abstract   PDF
Max Dahele, David Hwang, Chris Peressotti, Laibao Sun, Maggie Kusano, Shaista Okhai, Gail Darling, Martin Yaffe, Curtis Caldwell, Kathy Mah, Jennifer Hornby, Lisa Ehrlich, Simon Raphael, Ming Tsao, Yee C. Ung, A. Behzadi, C. Weigensberg
Vol 25, No 6 (2018) Developing a model of a patient-group pathway to accessing cancer clinical trials in Canada Abstract   PDF   HTML
G. Batist, S. Michaud, D. P. Richards, F. Servidio-Italiano, B. D. Stein
Vol 24, No 3 (2017) Development and pre-testing of a rehabilitation planning consultation for head-and-neck cancer Abstract   PDF   HTML
S. McEwen, C. Dunphy, J. Norman Rios, A. Davis, J. Jones, A. Lam, I. Poon, R. Martino, J. Ringash
Vol 24, No 5 (2017) Development of an online, patient-centred decision aid for patients with oropharyngeal cancer in the transoral robotic surgery era Abstract   PDF   HTML
J.S. Lam, G.M. Scott, D.A. Palma, K. Fung, A.V. Louie
Vol 16, No 2 (2009) Development of Cell Cycle Inhibitors for Cancer Therapy Details   PDF
Gary K. Schwartz, Mark Dickson
Vol 26, No 1 (2019) Diabetes mellitus secondary to treatment with immune checkpoint inhibitors Abstract   PDF   HTML
V. Venetsanaki, A. Boutis, A. Chrisoulidou, P. Papakotoulas
Vol 22, No 4 (2015) Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care? Abstract   PDF   HTML
R. VanderMeer, S. Chambers, A. Van Dam, J.C. Cutz, J.R. Goffin, P.M. Ellis
Vol 17, No 2 (2010) Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre Abstract   PDF
T. Asmis, F. Balaa, L. Scully, D. Papadatos, C. Marginean, N. Fasih, T. Shaw-Stiffel, R. Goel
Vol 26, No 5 (2019) Diagnosis and pathologic characteristics of medullary thyroid carcinoma—review of current guidelines Abstract   PDF   HTML
C. M. Thomas, S. L. Asa, S. Ezzat, A. M. Sawka, D. Goldstein
Vol 24, No 3 (2017) Diagnostic value of epidermal growth factor, cancer antigen 125, and cancer antigen 15-3 in bronchoalveolar lavage fluid of lung cancer Abstract   PDF   HTML
S. Sun, Z. Chen, C. Cao, B. Wu, B. Wang, Y. Yu, Z. Chen, Z. Hu, Z. Deng
Vol 21, No 1 (2014) Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer Abstract   PDF   HTML
E. Polat, U. Duman, M. Duman, A.E. Atici, E. Reyhan, T. Dalgic, E.B. Bostanci, S. Yol
Vol 23, No 4 (2016) Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study Abstract   PDF   HTML
S.F. Hall, R. Griffiths
Vol 13, No 4 (2006) Diffusion and dissemination of evidence-based dietary srategies for the prevention of cancer Details   PDF
Parminder Raina, Donna Ciliska, Paula Robinson, Tanya Armour, Peter Ellis, Melissa Brouwers, Mary Gauld, Fulvia Baldassarre
Vol 18, No 3 (2011) Digital necrosis induced by erlotinib treatment in metastatic adenocarcinoma of the lung Abstract   PDF   HTML
P. Ballardini, G. Margutti, R. Manfredini
Vol 26, No 2 (2019) Dignity and its influencing factors in patients with cancer in North China: a cross-sectional study Abstract   PDF   HTML
L. Wang, Y. Wei, L. Xue, Q. Guo, W. Liu
Vol 20, No 6 (2013) Direct cost for initial management of prostate cancer: a systematic review Abstract   PDF   HTML
C. Sanyal, A.G. Aprikian, S. Chevalier, F.L. Cury, A. Dragomir
Vol 19, No 2 (2012) Disappearing breast cancers Details   PDF   HTML
S.A. Narod
Vol 27, No 1 (2020) Discover the Canadian Association of Medical Oncologists Abstract   PDF   HTML
Various Authors
Vol 25, No 5 (2018) Discrepancies between Canadian cancer research funding and site-specific cancer burden: a spotlight on ten disease sites Abstract   PDF   HTML
A. C. Coronado, C. Finley, K. Badovinac, J. Han, J. Niu, R. Rahal
Vol 19, No 6 (2012) Disparities in timeliness of care for U.S. Medicare patients diagnosed with cancer Abstract   PDF   HTML
M.T. Halpern, D.J. Holden
Vol 19, No 6 (2012) Disparity in cancer care: a Canadian perspective Abstract   PDF   HTML
S. Ahmed, R.K. Shahid
Vol 22, No 6 (2015) Disparity in cancer prevention and screening in aboriginal populations: recommendations for action Abstract   PDF   HTML
S. Ahmed, R.K. Shahid, J.A. Episkenew
Vol 18, No 5 (2011) Distress—the 6th vital sign Details   PDF   HTML
D. Howell, K. Olsen
Vol 22, No 1 (2015) Distribution and clinical significance of TAMs in pancreatic ductal adenocarcinoma: A retrospective analysis in China Abstract   PDF   HTML
S.J. Chen, Q.B. Zhang, L.J. Zeng, G.D. Lian, J.J. Li, C.C. Qian, Y.Z. Chen, Y.T. Chen, K.H. Huang
Vol 15, No 5 (2008) Do Bone Metastases from Gastrointestinal Cancers Produce Similar Response Rates Following Radiotherapy When Compared to Bone Metastases from Other Primary Cancers? Abstract   PDF
Amanda Elizabeth Hird, Edward Chow, Darwin Yip, Michelle Ross, Stephanie Hadi, Candi Flynn, Emily Sinclair, Yoo-Joung Ko
Vol 20, No 1 (2013) Do current cancer follow-up care practices meet the needs of young adult cancer survivors in Canada? A qualitative inquiry Abstract   PDF   HTML
B. Miedema, J. Easley, L.M. Robinson
Vol 15, No 2 (2008) Do statins prevent or promote cancer? Abstract   PDF
Mark R Goldstein, Luca Mascitelli, Francesca Pezzetta
Vol 20, No 4 (2013) Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer? Abstract   PDF   HTML
T. Shenkier
Vol 22, No 3 (2015) Doctor, what are my options? A prospective cohort study of an individualized care plan for patients with gastrointestinal cancer Abstract   PDF   HTML
A.E. Hird, M. Lemke, M. Turovsky, V. Malecki, K. Kumar, C. DeAngelis, E. Chow, Y.J. Ko
Vol 24, No 1 (2017) Does adjuvant radiation therapy benefit women with small mammography-detected breast cancers? Abstract   PDF   HTML
K. Jerzak, N. Dudalski, K. Pritchard, P. Sun, S.A. Narod
Vol 13, No 1 (2006) Does Breast Cancer HER2/neu Overexpression influence Adjuvant Chemotherapy and Hormonal Therapy Choices of Ontario Physicians? ? A Physician Survey Details   PDF
Ellen Warner
Vol 22, No 6 (2015) Does CDKN2A loss predict palbociclib benefit? Abstract   PDF   HTML
J. Gao, R.P Adams, S.M. Swain
Vol 27, No 1 (2020) Does free nicotine replacement improve smoking cessation rates in cancer patients? Abstract   PDF   HTML
A. J Arifin, L. C. McCracken, S. Nesbitt, A. Warner, R. E. Dinniwell, D. A. Palma, A. V. Louie
Vol 19, No 4 (2012) Does neurologic deterioration help to differentiate between pseudoprogression and true disease progression in newly diagnosed glioblastoma multiforme? Abstract   PDF   HTML
A. D. Singh, J. C. Easaw
Vol 15, No 3 (2008) Does Preoperative PET/CT Predict Nodal Status in Endometrial Cancer? A Pilot Study Details   PDF
Janice S Kwon
Vol 26, No 5 (2019) Does the frequency of routine follow-up after curative treatment for head-and-neck cancer affect survival? Abstract   PDF   HTML
S. F. Hall, T. Owen, R. J. Griffiths, K. Brennan
Vol 25, No 6 (2018) Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients? Abstract   PDF   HTML
G. Kasymjanova, R. T. Jagoe, C. Pepe, L. Sakr, V. Cohen, D. Small, T. M. Muanza, J. S. Agulnik
Vol 15, No 2 (2008) Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in First-line Treatment of Advanced or Metastatic Adult Soft Tissue Sarcoma – A Clinical Practice Guideline Abstract   PDF
Denise Stys-Norman
Vol 23, No 1 (2016) Dosimetric and clinical toxicity comparison of critical organ preservation with three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and RapidArc for the treatment of locally advanced cancer of the pancreatic head Abstract   PDF   HTML
L. Jin, R. Wang, S. Jiang, J. Yue, T. Liu, X. Dou, K. Zhu, R. Feng, X. Xu, D. Chen, Y. Yin
401 - 500 of 1728 Items << < 1 2 3 4 5 6 7 8 9 10 > >>